Teva Pharma is trading 11.3% up today at $35.26 after its Q2 2026 earnings highlighted a major strategic milestone for its branded portfolio.
- Innovative brands Austedo, Ajovy, and Uzedy collectively exceeded $1 billion in quarterly revenue, representing 43% year-over-year growth.
- Investors are rewarding the pivot toward high-growth brands and overlooking an EPS miss caused by one-time charges from the Emalex acquisition.
- The stock is also benefiting from a broader healthcare sector rally driven by strong industry-wide earnings momentum.